Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Cash from Operations: 2014-2024

Historic Cash from Operations for Axsome Therapeutics (AXSM) over the last 11 years, with Dec 2024 value amounting to -$128.4 million.

  • Axsome Therapeutics' Cash from Operations rose 105.61% to $1.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$101.0 million, marking a year-over-year increase of 23.85%. This contributed to the annual value of -$128.4 million for FY2024, which is 11.49% up from last year.
  • Latest data reveals that Axsome Therapeutics reported Cash from Operations of -$128.4 million as of FY2024, which was up 11.49% from -$145.1 million recorded in FY2023.
  • Axsome Therapeutics' Cash from Operations' 5-year high stood at -$78.5 million during FY2020, with a 5-year trough of -$145.1 million in FY2023.
  • Moreover, its 3-year median value for Cash from Operations was -$128.4 million (2024), whereas its average is -$130.0 million.
  • Per our database at Business Quant, Axsome Therapeutics' Cash from Operations plummeted by 69.18% in 2020 and then climbed by 11.49% in 2024.
  • Axsome Therapeutics' Cash from Operations (Yearly) stood at -$78.5 million in 2020, then slumped by 37.94% to -$108.2 million in 2021, then dropped by 7.66% to -$116.5 million in 2022, then decreased by 24.52% to -$145.1 million in 2023, then climbed by 11.49% to -$128.4 million in 2024.